Wednesday 1st February 2017
|Text too small?|
Douglas Pharmaceuticals, the country's biggest drugs developer and manufacturer, has signed a research and licensing deal with the University of Manchester's innovation unit, UMI3, to repurpose an HIV drug to prevent early-stage cervical cancer.
Auckland-based Douglas Pharmaceuticals will sponsor research at Manchester University to build on work, including a phase one trial in Kenya, that's found a drug commonly used to treat HIV was active against human papilloma virus (HPV), which causes almost all cases of cervical cancer. Douglas Pharmaceuticals would then manufacture the therapy and drive development, clinical trials and global commercialisation, focusing at first on a phase two clinical trial in the UK.
Chief executive Jeff Douglas told BusinessDesk the company has been working with Manchester University for almost two years, and if clinical trials in American and European centres are successful, then they would partner with a multinational company for an international roll-out that could cost "more than tens of millions of dollars".
Douglas said the Gardasil HPV vaccine had been successful in reducing cervical cancer where it had been rolled out, primarily in the US and Europe, although it was still a relatively new treatment in developed economies.
"There will be other patients requiring treatment that haven't been protected in poorer countries," he said.
Douglas Pharmaceuticals is on track to reach annual sales of $200 million in the current financial year, and has previously set a target of $244 million in revenue by 2020.
Douglas said repurposing existing drugs is "an important addition to our business" and while it's "far more expensive than some other work" the returns are better if it's successful, and it can provide new patent protection.
The company has just set up a new development business in the US, with a team on board in Pennsylvania, which Douglas said he expects to be operational in three months.
No comments yet
MARKET CLOSE: NZ shares up 1%, led by Fisher & Paykel, Kathmandu, Spark
NZ dollar heads for 2% decline as resurgent US yields stoke greenback demand
Former Abano shareholders ordered to pay $429k in disputed takeover costs
Seeka shareholder Farmind to cut stake to reduce foreign ownership
Summerset opens Melbourne office as it looks to Australia for growth
Lees-Galloway signals broader health & safety targets in draft strategy
Veritas in refinancing negotiations as ANZ extends debt for a fourth time
ComCom embarks on fibre study to get a handle on looming new policy framework
NZ posts first trade deficit for March month in 10 years as fuel imports surge
NZ log export market picks up after slowdown ahead of Chinese New Year, traders optimistic